Biopôle is delighted to partner with IQVIA on the following seminar:

A New World of Real-World Evidence Generation to Maximize Asset Value.

This interactive seminar will focus on learning about the use of real-world evidence (RWE) and how it is increasingly being used across the product lifecycle to maximize the asset value, de-risk development and accelerate clinical programs.

On the 23rd November 2023, Michelle Bulliard, VP, Global Lead RWE, IQVIA, Maurice Straetmans, Director Key Account Management, MedTech, IQVIA and Olivier Humbey, Director Business Development, Real World Evidence Biotech, IQVIA will focus on the following topics:

Defining real-world evidence and real-world data (RWD)
How the RWE market and regulatory landscape is evolving
How RWE can be used to maximize asset value
Exploring the future use of RWE

At the end of this seminar you will

Understand what is RWE and RWD
Learn how RWE can be used across the total product lifecycle
Learn how to start evidence planning early with the end in mind

The format of this seminar will be delivered as a live presentation with interactive Q&A and discussion. Case studies that will also be presented highlighting and bring to life real examples on how RWE can successfully be used to meet the evidentiary needs of multi stakeholders.

This seminar covers a high level overview that would be relevant to anyone involved in product lifecycle development across all life science and medtech sectors from molecule, to market, to patient.

Agenda :

12:10 : Welcome

Welcome & Introductions
Agenda & learning objectives

12:15 : The Value of RWE

Defining real-world evidence (RWE) and real-world data (RWD)
What is driving the need for RWE?
Overview of the evolving regulatory landscape
Case study
Key takeaways

The use of RWE to maximize asset value

How the use of RWE creates value opportunities across the product lifecycle
Case Study
Key takeaways

De-risk innovation using RWE

Evidence planning
The future use of RWE
Key takeaways

13:30 : Lunch & Networking